Advertisement

Journal of Nuclear Cardiology

, Volume 18, Issue 6, pp 1086–1094 | Cite as

A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging

  • Fadi G. HageEmail author
  • Phillip Dean
  • Fahad Iqbal
  • Jaekyeong Heo
  • Ami E. Iskandrian
Original Article

Abstract

Background

Regadenoson myocardial perfusion imaging (MPI) is a useful method for risk assessment. We hypothesized that the heart rate response (HRR) to regadenoson carries incremental prognostic information to that derived from perfusion pattern and left ventricular (LV) ejection fraction (EF).

Methods and Results

The study population included 1,156 (60 ± 13 years, 46% women, 40% diabetes mellitus, 53% chronic kidney disease) patients. During a follow-up period of 22 ± 5 months, 103 patients died (9%). Independent determinants of the HRR included age, gender, race, diabetes mellitus, coronary revascularization, LVEF, use of insulin and aldosterone antagonists. Decreasing HRR was associated with stepwise increase in mortality (log-rank P < .0001). In a Cox proportional model for mortality that adjusted for age, gender, diabetes mellitus, renal disease, and MPI findings, HRR in the lowest quartile was independently associated with fivefold increase in mortality compared to the highest quartile [HR 5.2, 95% CI 2.3-12.0, P < .0001]. Patients with a normal HRR had a relatively low annualized total mortality despite the presence of risk factors. The addition of HRR to traditional MPI findings had a net reclassification improvement of 15%, P = .02.

Conclusion

A blunted HRR to regadenoson is an independent predictor of poor outcome, adds incremental value to MPI, and helps in better risk stratification.

Key Words

Regadenoson heart rate response myocardial perfusion imaging risk stratification 

Notes

Conflict of interest

Ami Iskandrian has received research funds from Astellas and served as consultant for Gilead.

References

  1. 1.
    Iskandrian AE, Garcia EV. Nuclear cardiac imaging: Principles and applications. Oxford: Oxford University Press; 2008.Google Scholar
  2. 2.
    Al Jaroudi W, Iskandrian AE. Regadenoson: A new myocardial stress agent. J Am Coll Cardiol 2009;54:1123-30.PubMedCrossRefGoogle Scholar
  3. 3.
    Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645-58.PubMedCrossRefGoogle Scholar
  4. 4.
    Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging: Integrated ADVANCE-MPI trial results. J Am Coll Cardiol Cardiol Imaging 2008;1:307-16.Google Scholar
  5. 5.
    Hage FG, Heo J, Franks B, Belardinelli L, Blackburn B, Wang W, et al. Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J 2009;157:771-6.PubMedCrossRefGoogle Scholar
  6. 6.
    Hage FG, Perry G, Heo J, Iskandrian AE. Blunting of the heart rate response to adenosine and regadenoson in relation to hyperglycemia and the metabolic syndrome. Am J Cardiol 2010;105:839-43.PubMedCrossRefGoogle Scholar
  7. 7.
    Abidov A, Hachamovitch R, Hayes SW, Ng CK, Cohen I, Friedman JD, et al. Prognostic impact of hemodynamic response to adenosine in patients older than age 55 years undergoing vasodilator stress myocardial perfusion study. Circulation 2003;107:2894-9.PubMedCrossRefGoogle Scholar
  8. 8.
    Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. A prognostic score for prediction of cardiac mortality risk after adenosine stress myocardial perfusion scintigraphy. J Am Coll Cardiol 2005;45:722-9.PubMedCrossRefGoogle Scholar
  9. 9.
    Bhatheja R, Francis GS, Pothier CE, Lauer MS. Heart rate response during dipyridamole stress as a predictor of mortality in patients with normal myocardial perfusion and normal electrocardiograms. Am J Cardiol 2005;95:1159-64.PubMedCrossRefGoogle Scholar
  10. 10.
    Mathur S, Shah AR, Ahlberg AW, Katten DM, Heller GV. Blunted heart rate response as a predictor of cardiac death in patients undergoing vasodilator stress technetium-99m sestamibi gated SPECT myocardial perfusion imaging. J Nucl Cardiol 2010;17:617-24.PubMedCrossRefGoogle Scholar
  11. 11.
    Venkataraman R, Hage FG, Dorfman TA, Heo J, Aqel RA, de Mattos AM, et al. Relation between heart rate response to adenosine and mortality in patients with end-stage renal disease. Am J Cardiol 2009;103:1159-64.PubMedCrossRefGoogle Scholar
  12. 12.
    Hage FG, Dean P, Bhatia V, Iqbal F, Heo J, Iskandrian AE. The prognostic value of the heart rate response to adenosine in relation to diabetes mellitus and chronic kidney disease. Am Heart J 2011. doi: 10.1016/j.ahj.2011.05.014.
  13. 13.
    Hage FG, Iskandrian AE. Heart rate response during vasodilator stress myocardial perfusion imaging: Mechanisms and implications. J Nucl Cardiol 2010;17:536-9.PubMedCrossRefGoogle Scholar
  14. 14.
    Hage FG, Dubovsky EV, Heo J, Iskandrian AE. Outcome of patients with adenosine-induced ST-segment depression but with normal perfusion on tomographic imaging. Am J Cardiol 2006;98:1009-11.PubMedCrossRefGoogle Scholar
  15. 15.
    Hage FG, Venkataraman R, Aljaroudi W, Bravo PE, McLarry J, Faulkner M, et al. The impact of viability assessment using myocardial perfusion imaging on patient management and outcome. J Nucl Cardiol 2010;17:378-89.PubMedCrossRefGoogle Scholar
  16. 16.
    Germano G, Kavanagh PB, Berman DS. An automatic approach to the analysis, quantitation and review of perfusion and function from myocardial perfusion SPECT images. Int J Card Imaging 1997;13:337-46.PubMedCrossRefGoogle Scholar
  17. 17.
    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.Google Scholar
  18. 18.
    Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72. discussion 207-12.PubMedCrossRefGoogle Scholar
  19. 19.
    Maser RE, Lenhard MJ. Cardiovascular autonomic neuropathy due to diabetes mellitus: Clinical manifestations, consequences, and treatment. J Clin Endocrinol Metab 2005;90:5896-903.PubMedCrossRefGoogle Scholar
  20. 20.
    Vashist A, Heller EN, Blum S, Brown EJ, Bhalodkar NC. Association of heart rate response with scan and left ventricular function on adenosine myocardial perfusion imaging. Am J Cardiol 2002;89:174-7.PubMedCrossRefGoogle Scholar
  21. 21.
    Mansur SJ, Hage FG, Oparil S. Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted? Curr Cardiol Rep 2010;12:450-63.PubMedCrossRefGoogle Scholar
  22. 22.
    Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet 2006;45:1201-12.PubMedCrossRefGoogle Scholar
  23. 23.
    Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol 2007;47:825-33.PubMedCrossRefGoogle Scholar
  24. 24.
    Hage FG, Iskandrian AE. Cardiac autonomic denervation in diabetes mellitus. Circ Cardiovasc Imaging 2011;4:79-81.PubMedCrossRefGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 2011

Authors and Affiliations

  • Fadi G. Hage
    • 1
    • 2
    Email author
  • Phillip Dean
    • 3
  • Fahad Iqbal
    • 1
  • Jaekyeong Heo
    • 1
  • Ami E. Iskandrian
    • 1
  1. 1.Division of Cardiovascular DiseaseUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Division of CardiologyBirmingham Veterans Affairs Medical CenterBirminghamUSA
  3. 3.Department of MedicineUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations